Skip to main content
COGT logo

Cogent Biosciences, Inc. (COGT) Stock: Price, Forecast & Analyst Target

Cogent Biosciences, Inc. (COGT) — MoonshotScore 50/100 (Fair band), calculated Nov 18, 2026. Price $27.74 (-0.25%), as of the Nov 19, 2026 trading session; market cap $4.83B.

Educational signal · not a buy or sell recommendation · How to read this

$27.74 −$0.07 (-0.25%) Market Cap $4.83B

Cogent Biosciences, Inc. · COGT · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Cogent Biosciences is a clinical-stage biotechnology company developing targeted therapies for genetic mutations that drive blood and gastrointestinal cancers, with its lead candidate in late-stage trials. The central question is whether the lead program advances to regulatory approval and commercial launch, generating revenue that transitions the company from burn-rate dependent to cash-generative; if the program fails, cash runway becomes the critical metric.

Price as of Nov 19, 2026

Key Statistics

50 of 100

MoonshotScore v2 · Cogent Biosciences (COGT)

Fair
Business Quality Thin (34)
Financial Safety Okay (47)
Valuation Full (46)
Growth Durability Fading (30)
Momentum Quiet (53)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, weak growth and a full valuation, though the balance sheet is only middling. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z 5.99 · Piotroski F 2
  • ROE -99.6% · ROA -42.0% · current ratio 10.99

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for COGT (57 recorded, newest six shown)
RecordedScoreBand
51Fair
51Fair
50Fair
50Fair
50Fair
50Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$27.74
Change on the day-0.25%
52-week range$26.46–$43.73
Market capitalisation$4.83B—
Price / earnings (trailing)-37.99
Shares traded on the day1.68M
Beta (volatility vs the S&P 500)0.34

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $15, high $42, latest $28. $42 $15 high $42 Oct 17, 2025 Nov 19, 2026 · $28 $16Oct 17, 2025$16Oct 31, 2025$34Nov 14, 2025$40Nov 28, 2025$42Dec 12, 2025$39Dec 26, 2025$35Jan 9, 2026$37Jan 23, 2026$37Feb 6, 2026$37Feb 20, 2026$37Mar 6, 2026$33Mar 20, 2026$35Apr 2, 2026$37Apr 17, 2026$37May 1, 2026$33May 15, 2026$35May 29, 2026$33Jun 12, 2026$38Jun 26, 2026$39Jul 10, 2026$40Jul 24, 2026$42Aug 7, 2026$37Aug 21, 2026$35Sep 4, 2026$32Sep 18, 2026$31Oct 2, 2026$30Oct 16, 2026$31Oct 30, 2026$29Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Cogent Biosciences (COGT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Neutral
Growth Durability Weak
Momentum Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Neutral
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Cogent Biosciences (COGT), and what does it report?

Short answer · as of

Cogent does not sell products and generates no revenue.

It is a development-stage company that executes research and clinical trials, burning through cash as it tests whether its targeted therapies work and are safe enough for regulatory approval.

The financial statements show research and development expenses as the primary operating cost, plus overhead for corporate and support functions. Without revenue, every metric—gross margin, operating margin, returns on assets—is negative by definition. The only metric that matters is cash runway and the likelihood that the lead program advances.

2 · Latest results

What do the latest results show for Cogent Biosciences (COGT)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

The company continues to report operating losses each quarter, as expected for an unfunded clinical-stage program. The operating cash burn rate has been steady, suggesting the company is executing its development timeline without major setbacks or accelerations.

There are no revenue or earnings surprises at a company with no revenue. The signal lies in whether the company announces clinical trial progress, regulatory meetings, or partnership achievements that reduce execution risk. Management guidance on cash runway is the most relevant metric.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

3 · Financial strengths and risks

What are the financial strengths and risks for Cogent Biosciences (COGT)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The company maintains a substantial cash balance sufficient to fund operations for multiple years at the current burn rate. However, cash is finite; once depleted, the company must either achieve financing through equity issuance, debt, or partnership with a larger pharmaceutical company.

The risk is not imminent insolvency but dilution to shareholders if the company must raise capital at unfavorable terms. A major clinical setback could accelerate the burn rate, shortening runway. The company has debt, which would be senior to equity in a restructuring.

Data-derived red flags

  • Negative return on equity (-99.6%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Cogent Biosciences (COGT)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $5.44M · EPS -2.33 · 7 analysts.

Watch for announcements from the lead clinical trial: interim data results, dosing decisions, or regulatory feedback. Any material update is a catalyst for stock repricing and a signal of whether the program remains viable.

Monitor cash balance trends and any announcement of financing activity, partnership, or licensing arrangements. Such announcements would alter the runway calculation and capital structure.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for COGT.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Cogent Biosciences compare with its peers?

Short answer

Cogent Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Cogent differs from commercial pharma companies by having no approved products, no manufacturing scale, and no sales infrastructure. Its value depends entirely on the probability that its lead program succeeds and the estimated commercial opportunity if it does.

Against other clinical-stage biotech, Cogent's value relative to cash runway depends on the quality of its trial data and the magnitude of unmet medical need in its target populations. Investors are betting on clinical success probability and magnitude of future market opportunity, not on current operations.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Same industry, near in market value$27.61 Nov 18, 2026$3.49B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$41.17 Nov 19, 2026$4.51B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$19.50 Nov 18, 2026$5.59B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.41 Nov 19, 2026$3.42B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Same industry, near in market value$17.83 Nov 18, 2026$3.08B68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$14.22 Nov 19, 2026$4.99B67 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$124.39 Nov 19, 2026$5.25B66 5-pillar Nov 18, 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Same industry, near in market value$26.20 Nov 19, 2026$3.37B66 5-pillar Nov 18, 2026
Cogent Biosciences (COGT) — this page$27.74$4.83B50

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$45.00 – $55.00
Consensus target
$50.67
Median target
$52.00
Revenue estimate
$5.44M
EPS estimate
$-2.33

Consensus record · Captured .

Measured against a quoted price of $27.74 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026

Transactions
14
Identified insiders
6
Purchases
0
Sales
2
Other transactions
12

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held COGT in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20260.16%$7.08MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Cogent Biosciences (COGT)?

Read these with our analysis →

Cogent Biosciences Healthcare Stock: Key Questions Answered

The last 2 questions are answered from this page's own dated data, not from the research.

What is CGT-something and why would it work?

Cogent's lead candidate is a targeted inhibitor designed to block a specific genetic mutation. The company has selected patients with the mutation and is testing whether blocking the target leads to clinical benefit. Success would mean regulators approve the drug and physicians prescribe it for patients with the mutation. Failure means the target either does not work or the drug is unsafe.

When will Cogent have revenue?

Revenue depends on whether the lead program gains regulatory approval and whether the company maintains the commercial rights (or partnerships with a larger firm to commercialize). Timeline estimates suggest potential approval and launch are years away. Analysts forecast revenue beginning in later fiscal periods, but these estimates depend on clinical trial success, which is inherently uncertain.

Should I buy this stock if I think the drug will work?

Stock price will largely track clinical trial progress and cash runway. If you are confident the drug will work, the question is valuation: whether current market price reflects fair odds of success and reasonable upside if it does. Biotech valuations are volatile; a single setback can halve the stock, and a strong trial result can double it. Position sizing matters more than conviction.

What is the dilution risk if the company needs to raise capital?

If Cogent must issue equity before the lead program launches, current shareholders will be diluted by the percentage that new shares represent. The magnitude depends on how much capital the company needs and at what valuation it can raise. Investors should monitor cash balance and management guidance on future capital needs to anticipate dilution likelihood and timing.

What is the COGT stock price today?

The last price recorded for Cogent Biosciences, Inc. (COGT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the COGT price target?

The analyst consensus price target for Cogent Biosciences, Inc. (COGT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Annual revenue and net result (USD millions); Cash runway cross-check (ours)
  • 1. What is Cogent Biosciences (COGT), and what does it report?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Cash runway cross-check (ours)
  • 2. What do the latest results show for Cogent Biosciences (COGT)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash runway cross-check (ours)
  • 3. What are the financial strengths and risks for Cogent Biosciences (COGT)?: Cash, investments and debt; Cash runway cross-check (ours); Trailing twelve-month ratio set
  • 4. What should you watch next at Cogent Biosciences (COGT)?: Next earnings report; Analyst revenue and earnings estimates (average); Recent SEC filings
  • 5. How does Cogent Biosciences compare with its peers?: Business description; Analyst revenue and earnings estimates (average); Cash runway cross-check (ours)
  • FAQ: What is CGT-something and why would it work?: Business description; Analyst revenue and earnings estimates (average)
  • FAQ: When will Cogent have revenue?: Analyst revenue and earnings estimates (average); Annual revenue and net result (USD millions)
  • FAQ: Should I buy this stock if I think the drug will work?: Cash runway cross-check (ours); Analyst revenue and earnings estimates (average)
  • FAQ: What is the dilution risk if the company needs to raise capital?: Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Most recent Schedule 13D
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.